Cantargia

34 articles about Cantargia

• Cantargia Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in a Leading Scientific Journal

  4/10/2024

  Cantargia Cantargia reported publication of preclinical results obtained with CAN10 in systemic sclerosis in one of the leading rheumatology journals, ‘Annals of the Rheumatic Diseases'.

• Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

  4/2/2024

  Cantargia Cantargia reported publication of promising preclinical data supporting the potential of the anti-IL1RAP antibody CAN10 as treatment of atherosclerosis.

• Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia

  3/27/2024

  Cantargia Cantargia reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia or myelodysplastic syndrome.

• Cantargia Publishes Year-End Report for 2023

  2/22/2024

  Cantargia Cantargia announced its interim report for the fourth quarter and year-end 2023.

• Invitation to Presentation of Cantargia’s Year-End Report 2023 on February 22 at 3.00 p.m. CET

  2/7/2024

  Cantargia (STO:CANTA) Cantargia AB will publish the company's year-end report for 2023 on Thursday, February 22, 2024, at 07:00 a.m. CET.

• Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and CAN10

  11/24/2023

  Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data providing further support for its lead assets, the IL1RAP-binding antibodies nadunolimab (CAN04) and CAN10, in both cancer and cardiovascular disease.

• Cantargia Publishes Interim Report for Third Quarter 2023

  11/10/2023

  Cantargia Cantargia AB's interim report for the period January until September 2023 is now available on the company's web page

• BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

  11/26/2020

  Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.

• Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT® Technology

  8/23/2019

  Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.

• Cantargia Raises MSEK 24.6 Through Exercise Of Warrants

  10/24/2016

• Cantargia To Present New Data From Preclinical Studies With CAN04 In Non-Small Cell Lung Cancer

  10/20/2016

• Cantargia Prepares Intensified Development Strategy And Capital Raising

  9/20/2016

• Cantargia Interim Report January – June 2016

  8/24/2016

• Cantargia Raises kSEK 250 Through Exercise Of Warrants

  8/22/2016

• Cantargia Obtains A Granted Patent From USPTO Concerning Il1RAP In Solid Tumors

  7/15/2016

• Cantargia'’s CAN04 Product Candidate Show Very Good Safety At High Dose Levels, Paving The Way For Final GLP Toxicity Study In Autumn 2016

  6/10/2016

• Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Solid Tumors

  6/10/2016

• Cantargia Receives Patent Approval In Japan For Solid Tumors

  6/8/2016

• Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Acute Lymphatic Leukemia

  6/8/2016

• Cantargia Interim Report January – March 2016

  5/16/2016